AI assistant
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2025
Dec 16, 2025
31868_dirs_2025-12-16_739d6955-8527-482f-b022-88fbad7b4544.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2025-12-12
Reporting Person: Barnes Alane P (Chief Legal Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-12 | Common Stock | F | 8540 | $7.57 | Disposed | 336936 | Direct |
| 2025-12-15 | Common Stock | S | 21210 | $7.65 | Disposed | 315726 | Direct |
Footnotes
F1: Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.
F2: This transaction was made pursuant to a plan adopted by the reporting person on August 13, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.